AIM: To characterize thermal hypersensitivity in patients with constipation- and diarrhea-predominant irritable bowel syndrome (IBS). METHODS: Thermal pain sensitivity was tested among patients with diarrhea-predominant IBS (D-IBS) and constipation-predominant IBS (C-IBS) compared to healthy subjects. A total of 42 patients (29 female and 13 male; mean age 27.0 +/- 6.4 years) with D-IBS; 24 patients (16 female and eight male; mean age 32.5 +/- 8.8 years) with C-IBS; and 52 control subjects (34 female and 18 male; mean age 27.3 +/- 8.0 years) participated in the study. Thermal stimuli were delivered using a Medoc Thermal Sensory Analyzer with a 3 cm x 3 cm surface area. Heat pain threshold (HPTh) and heat pain tolerance (HPTo) were assessed on the left ventral forearm and left calf using an ascending method of limits. The Functional Bowel Disease Severity Index (FBDSI) was also obtained for all subjects. RESULTS: Controls were less sensitive than C-IBS and D-IBS (both at P < 0.001) with no differences between C-IBS and D-IBS for HPTh and HPTo. Thermal hyperalgesia was present in both groups of IBS patients relative to controls, with IBS patients reporting significantly lower pain threshold and pain tolerance at both test sites. Cluster analysis revealed the presence of subgroups of IBS patients based on thermal hyperalgesia. One cluster (17% of the sample) showed a profile of heat pain sensitivity very similar to that of healthy controls; a second cluster (47% of the sample) showed moderate heat pain sensitivity; and a third cluster (36% of the sample) showed a very high degree of thermal hyperalgesia. CONCLUSION: A subset of IBS patients had thermal hypersensitivity compared to controls, who reported significantly lower HPTh and HPTo. All IBS patients had a higher score on the FBDSI than controls. Interestingly, the subset of IBS patients with high thermal sensitivity (36%) had the highest FBDSI score compared to the other two groups of IBS patients.
AIM: To characterize thermal hypersensitivity inpatients with constipation- and diarrhea-predominant irritable bowel syndrome (IBS). METHODS: Thermal pain sensitivity was tested among patients with diarrhea-predominant IBS (D-IBS) and constipation-predominant IBS (C-IBS) compared to healthy subjects. A total of 42 patients (29 female and 13 male; mean age 27.0 +/- 6.4 years) with D-IBS; 24 patients (16 female and eight male; mean age 32.5 +/- 8.8 years) with C-IBS; and 52 control subjects (34 female and 18 male; mean age 27.3 +/- 8.0 years) participated in the study. Thermal stimuli were delivered using a Medoc Thermal Sensory Analyzer with a 3 cm x 3 cm surface area. Heat pain threshold (HPTh) and heat pain tolerance (HPTo) were assessed on the left ventral forearm and left calf using an ascending method of limits. The Functional Bowel Disease Severity Index (FBDSI) was also obtained for all subjects. RESULTS: Controls were less sensitive than C-IBS and D-IBS (both at P < 0.001) with no differences between C-IBS and D-IBS for HPTh and HPTo. Thermal hyperalgesia was present in both groups of IBS patients relative to controls, with IBS patients reporting significantly lower pain threshold and pain tolerance at both test sites. Cluster analysis revealed the presence of subgroups of IBS patients based on thermal hyperalgesia. One cluster (17% of the sample) showed a profile of heat pain sensitivity very similar to that of healthy controls; a second cluster (47% of the sample) showed moderate heat pain sensitivity; and a third cluster (36% of the sample) showed a very high degree of thermal hyperalgesia. CONCLUSION: A subset of IBS patients had thermal hypersensitivity compared to controls, who reported significantly lower HPTh and HPTo. All IBS patients had a higher score on the FBDSI than controls. Interestingly, the subset of IBS patients with high thermal sensitivity (36%) had the highest FBDSI score compared to the other two groups of IBS patients.
Authors: A D Sperber; S Carmel; Y Atzmon; I Weisberg; Y Shalit; L Neumann; A Fich; M Friger; D Buskila Journal: Am J Gastroenterol Date: 2000-04 Impact factor: 10.864
Authors: Motoyori Kanazawa; Olafur S Palsson; Syed I M Thiwan; Marsha J Turner; Miranda A L van Tilburg; Lisa M Gangarosa; Denesh K Chitkara; Shin Fukudo; Douglas A Drossman; William E Whitehead Journal: Am J Gastroenterol Date: 2008-08-05 Impact factor: 10.864
Authors: G Nicholas Verne; Nathan C Himes; Michael E Robinson; Kaundinya S Gopinath; Richard W Briggs; Bruce Crosson; Donald D Price Journal: Pain Date: 2003-05 Impact factor: 6.961
Authors: J-M Sabate; M Veyrac; F Mion; L Siproudhis; P Ducrotte; F Zerbib; J-C Grimaud; M Dapoigny; F Dyard; B Coffin Journal: Aliment Pharmacol Ther Date: 2008-06-09 Impact factor: 8.171
Authors: Charles J Vierck; Fong Wong; Christopher D King; Andre P Mauderli; Siegfried Schmidt; Joseph L Riley Journal: Clin J Pain Date: 2014-02 Impact factor: 3.442
Authors: Shannon M Smith; Robert H Dworkin; Dennis C Turk; Ralf Baron; Michael Polydefkis; Irene Tracey; David Borsook; Robert R Edwards; Richard E Harris; Tor D Wager; Lars Arendt-Nielsen; Laurie B Burke; Daniel B Carr; Amy Chappell; John T Farrar; Roy Freeman; Ian Gilron; Veeraindar Goli; Juergen Haeussler; Troels Jensen; Nathaniel P Katz; Jeffrey Kent; Ernest A Kopecky; David A Lee; William Maixner; John D Markman; Justin C McArthur; Michael P McDermott; Lav Parvathenani; Srinivasa N Raja; Bob A Rappaport; Andrew S C Rice; Michael C Rowbotham; Jeffrey K Tobias; Ajay D Wasan; James Witter Journal: J Pain Date: 2017-02-27 Impact factor: 5.820
Authors: Fong Wong; Anthony C Rodrigues; Christopher D King; Joseph L Riley; Siegfried Schmidt; Charles J Vierck; Andre P Mauderli Journal: Pain Res Treat Date: 2010-08-09
Authors: Anthony Rodrigues; Christopher D King; Fong Wong; Joseph L Riley; Siegfried Schmidt; Andre P Mauderli Journal: Pain Res Treat Date: 2012-02-28